Simulations Plus, Inc. (SLP)

Simulations Plus develops software that predicts how drugs will behave inside the human body before a single pill is tested in a person. The company sells simulation tools to pharmaceutical companies, allowing researchers to model drug absorption, distribution, metabolism, and elimination — often called ADME — using computational chemistry and pharmacokinetics rather than animal testing or early clinical experiments. For a pharma company developing a new drug, these simulations can cut months off research timelines, eliminate costly failed experiments, and focus development on the most promising compounds. It is a specialized corner of the software market, competing against both custom in-house modeling by large pharma companies and other niche simulation vendors.

The drug development problem

Bringing a new drug to market is expensive and slow. A pharmaceutical company might screen hundreds of thousands of compounds, find a handful with biological promise, test those candidates in cell cultures and animals, and finally run clinical trials in humans. The entire process typically takes ten to fifteen years and costs hundreds of millions of dollars. Most candidates fail somewhere along the way — they prove toxic, ineffective, or their pharmacology is wrong.

One of the earliest stumbling blocks is understanding how a drug behaves in the body. Will it be absorbed if taken orally? How quickly? Does the liver metabolize it so fast that the drug is useless before it reaches the target tissue? Does it accumulate to toxic levels over repeated doses? These are critical questions that determine whether a compound is worth pursuing. Historically, they were answered through animal testing, preclinical studies, and early-stage human trials — all of which are expensive and time-consuming.

Simulations Plus’ advantage

Simulations Plus competes by replacing some of that empirical testing with computational prediction. The company’s core software uses physiologically-based pharmacokinetic modeling — it simulates human physiology (the liver, kidneys, fat, lean tissue, blood flow) and models how drug molecules move through and interact with it. Given the physical and chemical properties of a compound, the software can predict how much of the drug will reach the target organ, how long it will stay there, and what concentrations are likely to be toxic.

This approach is powerful because it is fast and cheap. Running a simulation takes hours; running an animal study takes weeks or months. Running a simulation costs thousands of dollars; running an in-vivo study costs tens of thousands or more. For a pharma company evaluating fifty candidate molecules, simulations let researchers narrow the field before committing to expensive animal work. That speed and cost advantage is Simulations Plus’ fundamental moat.

The company also acquired GastroPlus, a related platform focused on predicting how drugs are absorbed in the gastrointestinal tract — a crucial step for oral medications. The combination of ADME prediction and absorption modeling gives Simulations Plus a broad toolkit that covers more of the early drug development workflow than competitors focused on just one piece.

The competitive landscape

Simulations Plus is not alone in this space. Large pharma companies like Pfizer and Merck have built sophisticated in-house modeling capabilities over decades, and they have no incentive to outsource that work to a vendor. Many contract research organizations (CROs) have acquired or built similar simulation tools to offer to clients. Academic institutions publish modeling software, some of it free or open-source. The company competes most directly against vendors like Certara and smaller pure-play modeling shops.

Simulations Plus’ edge is partly products — the breadth and accuracy of its simulation engines — and partly customer relationships. A pharma researcher who has built expertise in GastroPlus or PK-Sim workflows is unlikely to switch to a different platform lightly. The software is also specialized enough that a customer typically licenses multiple modules and integrates them into their internal discovery pipelines, creating switching costs. But that advantage can erode if competitors release superior tools or if in-house capabilities at large customers improve.

Revenue and business model

Simulations Plus’ revenue comes primarily from software licenses. Customers pay for perpetual licenses to use the software, or renewable annual subscriptions, plus service and support. Some revenue also comes from consulting — helping pharma clients set up and interpret simulations. The software business typically carries high gross margins, because the incremental cost of another license is near zero. The challenge is sales — each customer is a large pharma company with long sales cycles and multiple stakeholders (medicinal chemists, pharmacokineticists, regulatory specialists) who need to agree that the software is worth the investment.

The company also generates revenue from partnerships and data licensing. Simulations Plus maintains databases of drug properties and human physiology parameters that it sells or licenses to academic institutions and other research organizations. These sources are smaller but represent recurring revenue that is not tied to selling new licenses.

Pressures and risks

Simulations Plus faces several structural challenges. First, the pharma customers it relies on are consolidating — mergers create internal redundancy and reduce the number of independent companies making software purchasing decisions. A merged entity may have duplicate capabilities from both predecessor companies and may rationalize away use of an external tool.

Second, the scientific frontier is always advancing. As machine learning and artificial intelligence improve, the question of whether simulations or neural networks can better predict drug behavior becomes live. If a competitor or academic group publishes evidence that a different approach is more accurate, customers might migrate.

Third, regulatory risk: if regulatory agencies like the FDA begin to accept simulation data as a substitute for animal testing, that could expand Simulations Plus’ addressable market. But it could also open the door to free or cheaper academic tools that do the same job, eating into pricing power.

Fourth, the company depends heavily on R&D spending by its pharma customers. During industry downturns or cost-cutting episodes, software purchases are often deferred in favor of core discovery spending. The market for Simulations Plus is tied to how much the entire pharma industry invests in new drug development.

Understanding Simulations Plus as an investment

Anyone researching SLP should start with the company’s 10-K (SEC CIK 0001023459) and quarterly earnings reports to understand the composition of revenue — what percentage comes from software licenses versus consulting versus other sources — and the trajectory of customer counts and contract value. Watch for concentration: if a few customers represent a large share of revenue, the company is exposed to the risk that one large customer changes direction or consolidates away.

The most important metric is license growth and renewal rates. If a high percentage of customers renew their subscriptions and the company is winning new pharma accounts, that signals durable competitive position. If renewal rates are declining or sales are struggling to grow, that suggests customers are finding alternatives or reducing spend. The company’s research pipeline — whether it is developing new capabilities in machine learning, artificial intelligence, or other emerging areas — is also worth monitoring, because competitive dynamics in software move quickly and yesterday’s innovation can become table stakes in a few years.